Skip to main content
ICLR
NASDAQ Industrial Applications And Services

ICON Q2 Revenue Hits $2.06B, Book-to-Bill Surges to 1.51; Guidance Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$185
Mkt Cap
$13.643B
52W Low
$66.57
52W High
$203.91
52W Position info
178% above low
Off High info
9.3% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ICLR has more than doubled off its 52-week low of $66.57.

Summary

ICON posted Q2 revenue of $2.06 billion and a 1.51 book-to-bill, driving backlog to $23.4 billion. Adjusted EPS rose 2.4% sequentially to $2.56, and full-year guidance was reaffirmed.


Key Events · Earnings and Guidance · ICLR

  • Revenue and Earnings Beat

    Q2 revenue of $2,063.5M rose 1.4% sequentially; adjusted diluted EPS of $2.56 increased 2.4% from Q1 2026.

  • Record Book-to-Bill and Backlog

    Net business wins of $3,120M yielded a 1.51 book-to-bill, up 8.3% QoQ. Backlog reached $23.4B, up 3.0% from Q1.

  • Guidance Reaffirmed

    Full-year 2026 revenue guidance maintained at $7,850–$8,150M and adjusted diluted EPS at $10.00–$11.00.

  • Strong Cash Generation

    Free cash flow of $238.9M in Q2; net debt of $2.5B with leverage ratio of 1.8x adjusted EBITDA.


Analysis · ICLR · Industrial Applications And Services

ICON delivered a solid Q2 with revenue up 1.4% sequentially to $2.06 billion and adjusted EBITDA margin holding at 15.9%. The standout metric is net business wins of $3.12 billion — a 1.51 book-to-bill — signaling robust demand and pushing backlog to a record $23.4 billion. Adjusted EPS of $2.56 beat the prior quarter by 2.4%, and free cash flow of $239 million strengthened the balance sheet. Management reaffirmed full-year guidance, projecting confidence despite a $32.9 million loss on the Symphony Health disposal. This report matters because it demonstrates operational resilience and commercial momentum just two months after a major restatement and Nasdaq non-compliance notice — evidence that the business is stabilizing and the growth engine remains intact.

How filings like this one have moved

In the 30 days to Sep 12, 2026, 35.9% of the 1612 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ICLR was trading at $185.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $66.57 to $203.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ICLR - Latest Insights

ICLR
Sep 09, 2026, 4:31 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $159.51
Real-time Price: $169.31 info
Change: +$9.80 (+6%) info
Market Cap: $13.063B info
ICLR
Aug 06, 2026, 8:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $163.55
Real-time Price: $169.31 info
Change: +$5.76 (+4%) info
Market Cap: $13.063B info
ICLR
Aug 04, 2026, 8:39 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.00
Real-time Price: $169.31 info
Change: +$12.31 (+8%) info
Market Cap: $13.063B info
ICLR
Jul 30, 2026, 9:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $182.00
Real-time Price: $169.31 info
Change: -$12.69 (-7%) info
Market Cap: $13.063B info
ICLR
Jul 29, 2026, 4:55 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $178.18
Real-time Price: $169.31 info
Change: -$8.87 (-5%) info
Market Cap: $13.063B info